A study to assess the safety, tolerability and pharmacokinetics of tideglusib in subjects with hepatic impairment compared to healthy subjects.
AMO-02-MD-1-001
Phase 1 other active
Quick answer
A study to assess the safety, tolerability and pharmacokinetics of tideglusib in subjects with hepatic impairment compared to healthy subjects. for Hepatic impairment, Healthy subjects is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Hepatic impairment, Healthy subjects
- Phase
- Phase 1
- Modality
- other
- Status
- active